Regulus Therapeutics
RGLS
#7337
Rank
S$0.72 B
Marketcap
S$10.46
Share price
0.00%
Change (1 day)
428.25%
Change (1 year)

Regulus Therapeutics (RGLS) - Cash on Hand

Cash on Hand as of March 2025 : S$83.78 Million

According to Regulus Therapeutics's latest financial reports the company has S$83.78 Million in cash and cash equivalents.
A companyโ€™s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.

Regulus Therapeutics - Cash on Hand chart (from 2011 to 2025)

Cash on Hand by year

Year Cash on Hand Change
2024-12-31S$0.10 B228.14%
2023-12-31S$31.38 M-40.21%
2022-12-31S$52.49 M-35.69%
2021-12-31S$81.63 M98.49%
2020-12-31S$41.12 M-10.6%
2019-12-31S$46 M141.64%
2018-12-31S$19.03 M-76.31%
2017-12-31S$80.34 M-27.06%
2016-12-31S$0.11 B-31.73%
2015-12-31S$0.16 B-23.56%
2014-12-31S$0.21 B46.13%
2013-12-31S$0.14 B20.4%
2012-12-31S$0.11 B142.86%
2011-12-31S$49.39 M

Cash on Hand for similar companies or competitors

Company Cash on Hand differencediff. Country
Sanofi
SNY
S$9.28 B 10,987.15%๐Ÿ‡ซ๐Ÿ‡ท France
Biogen
BIIB
S$1.64 B 1,865.79%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
S$16.12 B 19,146.42%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
S$6.36 B 7,500.05%๐Ÿ‡ฌ๐Ÿ‡ง UK
GSK plc
GSK
S$5.03 B 5,910.43%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sangamo Therapeutics
SGMO
S$35.35 M-57.80%๐Ÿ‡บ๐Ÿ‡ธ USA
Dicerna Pharmaceuticals
DRNA
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA
Alnylam Pharmaceuticals
ALNY
S$4.59 B 5,387.79%๐Ÿ‡บ๐Ÿ‡ธ USA